
Dr. Elliot Israel presents the utility of eosinophils as a biomarker of type 2 inflammation and their role in the disease burden of asthma.
This infographic outlines how endotyping, phenotyping, and genotyping are interrelated concepts that are crucial for improving the way patients with COPD are characterized and how understanding these concepts can better optimize patient care
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.
Learn how to identify chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation using blood eosinophil (EOS) levels, understand the associated risks, and recognize factors that may influence EOS counts.
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients
ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.
Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.